Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Cue Health
MedTech
Testmaker Cue Health under investor pressure to change course
Cue’s stock value has since slid into sub-dollar territory, dropping nearly 98% from the high of $20 when it went public down to about 50 cents today.
Conor Hale
Aug 31, 2023 12:01pm
Cue wins FDA's first de novo nod for an at-home COVID test
Jun 7, 2023 10:13am
Still raking in COVID profits, Cue plots next at-home tests
Aug 11, 2022 11:04am
Testmaker Cue Health to lay off 170 manufacturing workers
Jun 27, 2022 4:15pm
High-tech's business model hasn't worked for the Cue COVID test
May 20, 2022 9:55am
Cue to develop omicron-specific COVID test with BARDA backing
Jan 7, 2022 10:10am